Clinical characteristics of HIV-infected patients with adjudicated heart failure

Abstract

Aims

HIV-infected persons may have elevated risks for heart failure, but factors associated with heart failure in the modern era of HIV therapy are insufficiently understood. Despite substantial disagreement between physician-adjudicated heart failure and heart failure diagnosis codes, few studies of HIV cohorts have evaluated adjudicated heart failure. We evaluated associations of HIV viremia, immunosuppression, and cardiovascular risk factors with physician-adjudicated heart failure.

Methods and results

We analyzed clinical characteristics associated with heart failure in a cohort of 5041 HIV-infected patients receiving care at an urban hospital system between 2000 and 2016. We also evaluated characteristics of HIV-infected patients who screened negative for heart failure, screened positive for possible heart failure but did not have heart failure after adjudication, and had adjudicated heart failure. HIV-infected patients with heart failure (N = 216) were older and more likely to be black, hypertensive, and have diabetes than HIV-infected patients without heart failure; heart failure with reduced ejection fraction was more common than heart failure with preserved ejection fraction. In our primary analyses restricted to HIV-infected patients whose heart failure diagnoses did not precede their HIV diagnoses (N = 149), peak HIV viral load ≥100,000 copies/mL (odds ratio (OR) 2.12, 1.28–3.52) and nadir CD4 T-cell count <200 cells/mm³ (OR 2.35, 1.04–5.31) were associated with significantly elevated odds of heart failure. Overall, 30.6% of patients with any diagnosis code of heart failure had adjudicated heart failure.

Conclusion

Higher peak HIV viremia and lower CD4 cell nadir are associated with significantly elevated odds of heart failure for HIV-infected persons. Physician adjudication of heart failure may be helpful in HIV cohorts.

Keywords

Heart failure HIV adjudication electronic cohort

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2014. HIV Surveillance Report. Atlanta, USA: CDC, 2015.

Palella

Jr Baker

Moorman

et al.

Investigators HIVOS. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27–34.

Feinstein

Bahiru

Achenbach

et al.

Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol 2015; 117: 214–220.

Trickey

May

Vehreschild

et al.

Antiretroviral Therapy Cohort Collaboration. Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy. PLoS One 2016; 11: e0160460–e0160460.

Butt

Chang

Kuller

et al.

Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med 2011; 171: 737–743.

Paisible

A-L

Chang

C-CH

So-Armah

et al.

HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr 2015; 68: 209–216.

Hsu

Marcus

et al.

Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol 2013; 61: 2288–2295.

Tseng

Secemsky

Dowdy

et al.

Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012; 59: 1891–1896.

Barnett

Hsue

. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med 2013; 34: 283–292.

10.

Friis-Moller

Ryom

Smith

et al.

on behalf of the D:A:D Study Group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prevent Cardiol 2016; 23: 214–223.

11.

Idris

Grobbee

Burgner

et al.

Cardiovascular manifestations of HIV infection in children. Eur J Prevent Cardiol 2015; 22: 1452–1461.

12.

Levy

Simon

Rios

et al.

Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am J Cardiol 1989; 63: 86–89.

13.

De Castro

d’Amati

Gallo

et al.

Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol 1994; 24: 1018–1024.

14.

Herskowitz

Vlahov

Willoughby

et al.

Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. J Am Coll Cardiol 1993; 71: 955–958.

15.

Manga

McCutcheon

Tsabedze

et al.

HIV and nonischemic heart disease. J Am Coll Cardiol 2017; 69: 83–91.

16.

Vachiat

McCutcheon

Tsabedze

et al.

HIV and ischemic heart disease. J Am Coll Cardiol 2017; 69: 73–82.

17.

Al-Kindi

El Amm

Ginwalla

et al.

Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities. Int J Cardiol 2016; 218: 43–46.

18.

Freiberg

Chang

Skanderson

et al.

Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study. JAMA Cardiol 2017; 2: 536–546.

19.

Hsue

Hunt

et al.

Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010; 3: 132–139.

20.

Holloway

Ntusi

Suttie

et al.

Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation 2013; 128: 814–822.

21.

Diaz-Zamudio

Dey

LaBounty

et al.

Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study. J Cardiovasc Magn Reson 2015; 17: 91–91.

22.

Janjua

Triant

Addison

et al.

HIV infection and heart failure outcomes in women. J Am Coll Cardiol 2017; 69: 107–108.

23.

Rosamond

Chang

Baggett

et al.

Classification of heart failure in the Atherosclerosis Risk in Communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail 2012; 5: 152–159.

24.

Goff

Jr Pandey

Chan

et al.

Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 2000; 160: 197–202.

25.

Felsen

Bellin

Cunningham

et al.

Development of an electronic medical record-based algorithm to identify patients with unknown HIV status. AIDS Care 2014; 26: 1318–1325.

26.

Moorman

Gordon

Rupp

et al.

for the Chronic Hepatitis Cohort Study Investigators. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study. Clin Infect Dis 2013; 56: 40–50.

27.

Wilke

Berg

Peissig

et al.

Use of an electronic medical record for the identification of research subjects with diabetes mellitus. Clin Med Res 2007; 5: 1–7.

28.

Ali

Rouse

. Practice audits: reliability of sphygmomanometers and blood pressure recording bias. J Hum Hypertens 2002; 16: 359–361.

29.

Myers

Godwin

Dawes

et al.

Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 2010; 55: 195–200.

30.

Quan

Saunders

et al.

IMECCHI Investigators. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008; 43: 1424–1441.

31.

Rouse

Marshall

. The extent and implications of sphygmomanometer calibration error in primary care. J Hum Hypertens 2001; 15: 587–591.

32.

Ives

Fitzpatrick

Bild

et al.

Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 1995; 5: 278–285.

33.

Bozzette

Ake

Tam

et al.

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702–710.

34.

Lee

Donovan

Austin

et al.

Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 2005; 43: 182–188.

35.

McCormick

Lacaille

Bhole

et al.

Validity of myocardial infarction diagnoses in administrative databases: a systematic review. PLoS One 2014; 9: e92286–e92286.

36.

Patel

Quan

Welsh

et al.

Validity and utility of ICD-10 administrative health data for identifying ST- and non-ST-elevation myocardial infarction based on physician chart review. CMAJ Open 2015; 3: E413–E418.

37.

Shah

Katz

Selvaraj

et al.

Phenomapping for novel classification of heart failure with preserved ejection fraction: clinical perspective. Circulation 2015; 131: 269–279.

38.

Iribarren

Tolstykh

Miller

et al.

Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. Am J Epidemiol 2012; 176: 1014–1024.

39.

Saczynski

Andrade

Harrold

et al.

A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Safe 2012; 21(Suppl 1): 129–140.

40.

Kim

Januzzi

Jr . Natriuretic peptide testing in heart failure. Circulation 2011; 123: 2015–2019.

41.

Opdahl

Ambale Venkatesh

Fernandes

et al.

Resting heart rate as predictor for left ventricular dysfunction and heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2014; 63: 1182–1189.

42.

Chahal

Bluemke

et al.

Heart failure risk prediction in the Multi-Ethnic Study of Atherosclerosis. Heart 2015; 101: 58–64.

43.

Borlaug

Paulus

. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32: 670–679.

44.

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 16: 233–270.

45.

Cannillo

D’Ascenzo

Grosso Marra

et al.

Heart failure in patients with human immunodeficiency virus: a review of the literature. J Cardiovasc Med 2015; 16: 383–389.

46.

Remick

Georgiopoulou

Marti

et al.

Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research. Circulation 2014; 129: 1781–1789.

47.

Choi

Vittinghoff

Deeks

et al.

Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25: 1289–1298.

48.

Price

Hoy

Ridley

et al.

Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men. Sex Health 2015; 12: 240–248.

49.

Secemsky

Scherzer

Nitta

et al.

Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals. JACC Heart Fail 2015; 3: 591–599.

50.

Blaylock

Byers

Gibbs

et al.

Longitudinal assessment of cardiac diastolic function in HIV-infected patients. Int J STD AIDS 2012; 23: 105–110.

51.

Cerrato

D’Ascenzo

Biondi-Zoccai

et al.

Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J 2013; 34: 1432–1436.

52.

Triant

Lee

Hadigan

et al.

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506–2512.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.28 MB